Do you want to read an article? Please log in or register.
Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT
COPD
RECOMMENDED
Related content
RECOMMENDED
Further Publications
Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences
Adv Ther.
Svedsater H, Doll HA, Macey J, Miles G, Bradshaw L, Vanya M
doi: 10.1007/s12325-018-0760-7.
Further Publications
Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of the IMPACT Trial
Chest.
Hanania NA, Mannino DM, Criner GJ, Dransfield MT, Han MK, Jones CE, Kilbride S, Lomas DA, Martin N, Martinez FJ, Singh D, Wise RA, Halpin DMG, Lima R, Lipson DA
doi: 10.1016/j.chest.2020.09.253.
COPD
Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial
Respir Res.
Maltais F, Naya IP, Vogelmeier CF, Boucot IH, Jones PW, Bjermer L, Tombs L, Compton C, Lipson DA, Kerwin EM
doi: 10.1186/s12931-020-01451-8.
Efficacy and Safety of an Aclidinium Bromide Treatment for 12 Weeks or Longer in Patients with Moderate-To-Severe COPD: A Meta-Analysis
COPD.
Zou Y, Xiao J, Yang DH, Li J, Chen Q
doi: 10.3109/
RECOMMENDED
COPD
Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups
Respir Med.
Bakerly ND, Woodcock A,
Collier S, Leather DA, New JP,
Crawford J, Harvey C, Vestbo J,
Boucot I
doi: 10.1016/j.rmed.2018.12.016.
AsthmaCOPD
Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey
Int J Chron Obstruct Pulmon Dis
Ding B, Small M
doi: 10.2147/COPD.S136314.
RECOMMENDED
COPD
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Am J Respir Crit Care Med.
Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Lettis S, Manchester P, Martin N, Midwinter D, Morris A, Pascoe SJ, Singh D, Wise RA, Martinez FJ, IMPACT investigators.
doi: 10.1164/rccm.201911-2207OC.
RECOMMENDED
COPD
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respir Res.
Day NC, Kumar S, Criner G, Dransfield M, Halpin DMG, Han MK, Jones CE, Kaisermann MC, Kilbride S, Lange P, Lomas DA, Martin N, Martinez FJ, Singh D, Wise R, Lipson DA
doi: 10.1186/s12931-020-01398-w.
COPD
Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
Int J Chron Obstruct Pulmon Dis.
Beeh KM, Beier J, Candler H, Wittig T
doi: 10.2147/COPD.S11765